GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » Enterprise Value

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Enterprise Value : $28.09 Mil (As of May. 22, 2024)


View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, EOM Pharmaceutical Holdings's Enterprise Value is $28.09 Mil. EOM Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2018 was $-5.66 Mil. Therefore, EOM Pharmaceutical Holdings's EV-to-EBIT ratio for today is -4.96.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, EOM Pharmaceutical Holdings's Enterprise Value is $28.09 Mil. EOM Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2018 was $-5.65 Mil. Therefore, EOM Pharmaceutical Holdings's EV-to-EBITDA ratio for today is -4.97.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, EOM Pharmaceutical Holdings's Enterprise Value is $28.09 Mil. EOM Pharmaceutical Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2018 was $0.00 Mil. Therefore, EOM Pharmaceutical Holdings's EV-to-Revenue ratio for today is .


EOM Pharmaceutical Holdings Enterprise Value Historical Data

The historical data trend for EOM Pharmaceutical Holdings's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings Enterprise Value Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.32 -18.58 -19.40 -10.73 -5.29

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.51 -5.12 -5.29 -3.98 -1.76

Competitive Comparison of EOM Pharmaceutical Holdings's Enterprise Value

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Enterprise Value distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Enterprise Value falls into.



EOM Pharmaceutical Holdings Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EOM Pharmaceutical Holdings's Enterprise Value for the fiscal year that ended in Dec. 2017 is calculated as

EOM Pharmaceutical Holdings's Enterprise Value for the quarter that ended in Jun. 2018 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

EOM Pharmaceutical Holdings's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=28.091/-5.664
=-4.96

EOM Pharmaceutical Holdings's current Enterprise Value is $28.09 Mil.
EOM Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.66 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

EOM Pharmaceutical Holdings's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=28.091/-5.65
=-4.97

EOM Pharmaceutical Holdings's current Enterprise Value is $28.09 Mil.
EOM Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.65 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

EOM Pharmaceutical Holdings's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=28.091/0
=

EOM Pharmaceutical Holdings's current Enterprise Value is $28.09 Mil.
EOM Pharmaceutical Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EOM Pharmaceutical Holdings Enterprise Value Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Headlines